Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Bisphosphonate-containing pharmaceutical vaccine composition for humoral immunity

一种双膦酸盐剂、体液免疫的技术，应用在药物组合、含有效成分的医用配制品、非有效成分的医用配制品等方向，能够解决不能期待治疗效果等问题

Inactive Publication Date: 2017-05-17
NITTO DENKO CORP
View PDF13 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] However, γδT cells only exist in 1 to 5% of peripheral blood, and a sufficient therapeutic effect cannot be expected only by administering bisphosphonates

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bisphosphonate-containing pharmaceutical vaccine composition for humoral immunity
  • Bisphosphonate-containing pharmaceutical vaccine composition for humoral immunity
  • Bisphosphonate-containing pharmaceutical vaccine composition for humoral immunity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1～20、 comparative example 1、2

[0141] (Preparation of Liquid Preparations for Transmucosal Administration)

[0142] Liquid preparations for transmucosal administration (nasal administration or sublingual administration) having the compositions in Tables 1 and 2 below were prepared. Specifically, an antigen (ovalbumin (OVA), manufactured by Sigma-Aldrich Co., Ltd.) and an immunity-inducing promoter as a bisphosphonate were compounded in the compounding amounts shown in the following Tables 1 and 2, and Physiological saline and mixed to obtain a liquid preparation for transmucosal administration (nasal administration or sublingual administration).

[0143] As the immune induction enhancer of the bisphosphonate, etidronate (manufactured by LKT Laboratories), clodronate (manufactured by LKT Laboratories), tiludronate (manufactured by Sigma-Aldrich), Pamidronate (manufactured by Sigma-Aldrich), neridronate (manufactured by Sigma-Aldrich), alendronate (manufactured by Medichem), ibandronate (manufactured by URQU...

Embodiment 21～32、 comparative example 3、4

[0149] (Preparation of solid preparation for sublingual administration)

[0150] Solid preparations for sublingual administration (lyophilized preparations or film preparations) having the compositions in Table 3 below were prepared. Specifically, an antigen (ovalbumin (OVA), manufactured by Sigma-Aldrich), an immunity-inducing enhancer as a bisphosphonate agent, a hydroxyl Physiological saline was added to propylcellulose (HPC-SSL, manufactured by Nippon Soda Co., Ltd.) and mixed to obtain a preparation solution. Then, 25 mg of the preparation solution was dispensed and freeze-dried to obtain a freeze-dried preparation or dried under reduced pressure to obtain a film preparation. As the immunity induction enhancer of the bisphosphonate preparation, the same substance as that used for the preparation of the liquid preparation for transmucosal administration was used.

[0151] [table 3]

[0152]

[0153]

[0154] The following evaluations were performed on the liquid pr...

Embodiment 33～42、 comparative example 5

[0168] (Preparation of Cream for Transdermal Administration)

[0169] A cream for transdermal administration having the composition of Table 4 below was prepared. Specifically, an antigen (ovalbumin (OVA), manufactured by Sigma-Aldrich) and an immunity-inducing enhancer as a bisphosphonate agent were compounded in the compounding amounts shown in the following Table 4, and the base material was added thereto. (Base cream) The total amount was adjusted to 100 parts by weight, and mixed to obtain a cream for transdermal administration. The base cream used was prepared by compounding and kneading materials according to the composition described in Table 5.

[0170] As the immune induction promoter of the bisphosphonate preparation, the same substance as that used for the preparation of the liquid preparation for nasal cavity or sublingual administration was used. White petrolatum, sorbitan monostearate, isostearic acid, benzyl alcohol, stearyl alcohol, Tween 60, concentrated gl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The purpose of the present invention is to provide a pharmaceutical vaccine composition that is universally usable for inducing humoral immunity against various antigens and exerts an excellent effect of inducing antibody production. Provided is a pharmaceutical vaccine composition for inducing humoral immunity, said pharmaceutical vaccine composition comprising an antigen and an immunity induction promoter that is a bisphosphonate.

Description

technical field [0001] The present invention relates to a vaccine pharmaceutical composition for humoral immunity induction. Background technique [0002] Generally, widely used vaccines are aimed at inducing immunity for the prevention of infectious diseases, and are administered to pathogens such as microorganisms or viruses or parts thereof. Most of the currently commercialized vaccine preparations are injections. [0003] Usually, the invasion of microorganisms or viruses into the body due to their size is prevented by the skin, therefore, vaccines must be administered invasively into the body. Therefore, immunization by vaccines is usually administered by subcutaneous injection, intradermal injection, intramuscular injection or the like. [0004] As an adjuvant or immunoactivator for immunization by injection, aluminum hydroxide, aluminum phosphate, aluminum salts such as aluminum chloride, emulsions containing squalene such as MF59 and AS03, etc. Flagellar component...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K31/663A61K39/39A61P37/04
CPCA61K39/00A61K39/39A61K31/663A61K47/548A61K39/395A61K2039/55511A61K2039/58
Inventor 宍户卓矢浅利大介堀光彦
Owner NITTO DENKO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com